Friday, 28 November 2014

Journal of Medical Economics: A cost comparison of long-acting insulin analogues versus NPH insulin-based treatment T2D 

Following insulin initiation, the difference in healthcare costs of long-acting analogues compared to NPH insulin was transient. By year 3, the cost differences were not significantly different between the two cohorts, driven by an observed reduction in the cost of self-monitoring of blood glucose (SMBG) in the analogue group and an increase in the cost of bolus insulin in the NPH group ~(Journal Medical Economics)

Thursday, 27 November 2014

Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial

Single-hormone and dual-hormone artificial pancreas systems both provided better glycaemic control than did conventional insulin pump therapy. The single-hormone artificial pancreas might be sufficient for hypoglycaemia-free overnight glycaemic control (The Lancet Diabetes & Endocrinology)

Offer weight loss surgery to obese people with diabetes

The NHS should offer weight loss surgery to thousands more people in order to tackle an epidemic of type 2 diabetes, says NICE

Glyoxylate, a New Marker Metabolite of Type 2 Diabetes

A retrospective study using samples of long-term blood donors revealed that glyoxylate levels unlike glucose levels became significantly elevated up to 3 years prior to diabetes diagnosis (Journal of Diabetes Research)

Wednesday, 26 November 2014

The durability of sitagliptin in elderly patients with type 2 diabetes

Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients. This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM (Clinical Interventions in Aging)

Tuesday, 25 November 2014

Risk of cardiovascular disease: The effects of diabetes and anti-diabetic drugs — A nested case–control study

We have shown an association between the use of biguanides and liraglutide and a reduced risk of composite endpoint in DM patients (International Journal of Cardiology)

Primary care screening for individuals with impaired glucose metabolism with focus on impaired glucose tolerance

The Skövde Form combined with a random plasma glucose may be used as an alternative tool for detection of individuals with IGM and IGT in particular. HbA1c may be used to identify individuals with type 2 diabetes but fails to detect most individuals with prediabetes (Primary Care Diabetes)

Monday, 24 November 2014

A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes

Atorvastatin lowered LDL-C, apoB, and atherogenic lipoprotein subparticles in children with T1D and elevated LDL-C without worsening insulin resistance. The drug was well tolerated and safe. Long-term studies would provide better insight on the impact of these interventions in the development of cardiovascular disease in children with diabetes (Pediatric Diabetes)

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis

DPP-4 inhibitors are effective at lowering HbA1c in T2DM patients with moderate to severe renal impairment. DPP-4 inhibitors also have a potential advantage in lowering the risk of adverse events (PLoS ONE)

Endothelial Dysfunction Plays a Key Role in Increasing Cardiovascular Risk in Type 2 Diabetes

Endothelial dysfunction and type 2 diabetes mellitus, IGM, or insulin resistance synergistically increase cardiovascular event risk. This identifies endothelial dysfunction as a key therapeutic target in these individuals (Hypertension)

Friday, 21 November 2014

Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High-Risk Patients With Diabetes

Among asymptomatic patients with type 1 or type 2 diabetes, use of CCTA to screen for CAD did not reduce the composite rate of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalization at 4 years. These findings do not support CCTA screening in this population (JAMA)

Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations

The evidence from 15 randomized prospective studies supports the combined use of a GLP-1 receptor agonist with basal insulin in a broad range of patients with uncontrolled type 2 diabetes (Drugs)

Victoza® receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal impairment

Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments (Novo Nordisk)

Thursday, 20 November 2014

Glycemic Control and Excess Mortality in Type 1 Diabetes

In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls (NEJM)

Wednesday, 19 November 2014

Glucose uptake in brown fat cells is dependent on mTOR complex 2–promoted GLUT1 translocation

Brown adipose tissue is the primary site for thermogenesis and can consume, in addition to free fatty acids, a very high amount of glucose from the blood, which can both acutely and chronically affect glucose homeostasis Journal of Cell Biology)

The Effect of the Endoscopic Duodenal-Jejunal Bypass Liner on Obesity and Type 2 Diabetes Mellitus, a Multicenter Randomized Controlled Trial

The DJBL is a safe and effective alternative to invasive bariatric procedures. Six months of DJBL treatment combined with diet leads to superior weight loss and improvement of T2DM when compared with diet alone (Annals of Surgery)

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for =24 weeks in eyes with DME involving the central macula with vision impairment (Ophthalmology)

Monday, 17 November 2014

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Empagliflozin tablets reduced hemoglobin A1C, body weight and several markers of abdominal fat in adults with type 2 diabetes, according to a new retrospective analysis of clinical trial data presented on behalf of Boehringer Ingelheim and Eli Lilly at the 2014 Scientific Sessions of the American Heart Association in Chicago

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

The investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN® (ezetimibe/simvastatin) – which combines simvastatin with the non-statin ZETIA® (ezetimibe) -- experienced significantly fewer major cardiovascular events than patients treated with simvastatin alone (Merck)

Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies

Treatment with ACE/ARBs results in significant reduction in CV events and mortality in hypertensive patients with T2 DM (BMC Cardiovascular Disorders)

All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used?

In our cohort of T2DM outpatients, different eGFR equations perform similarly in predicting ACM, whereas SCr did not (Diabetes and Vascular Disease Research)

Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis

The protective effect of metformin against free fatty acid induced apoptosis is potentially clinically relevant as metformin is first line treatment for patients with T2D, a patient group which is rapidly increasing and carries a high burden of cardiovascular disease (Cardiovascular Diabetology)

The Access to Medicine Index 2014 

The fourth Access to Medicine Index report provides a finely detailed picture of how the world’s 20 largest research-based pharmaceutical companies address access to medicine. Ranking (Access to Medicine Foundation)

Diabetes self-management education: acceptability of using trained lay educators

Positive perceptions about the use of lay educators support the positive quantitative findings from the main trial. Acceptability is an important consideration in relation to implementation of the model of delivery studied. Concerns raised within the interviews should be considered in the design of training for lay educators (Postgraduate Medical Journal)

Friday, 14 November 2014

Evaluating peripheral nerve function in asymptomatic patients with Type 2 diabetes or latent autoimmune diabetes of adults (LADA): results from nerve conduction studies

Peripheral nerve dysfunction is common in asymptomatic patients with LADA or T2DM. Findings of the study suggest that LADA and T2DM differ in the pattern of peripheral nerve involvement over diabetes duration (Diabetes and Its Complications)

Thursday, 13 November 2014

Evidence of early alterations in adipose tissue biology and function and its association with obesity-related inflammation and insulin resistance in children

we show that adipocyte hypertrophy is linked to increased inflammation in AT in obese children thereby providing evidence that obesity-associated AT dysfunction develops in early childhood and is related to insulin resistance (Diabetes)

Wednesday, 12 November 2014

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

Heart failure and peripheral arterial disease are the most common initial manifestations of cardiovascular disease in type 2 diabetes. The differences between relative risks of different cardiovascular diseases in patients with type 2 diabetes have implications for clinical risk assessment and trial design (The Lancet Diabetes & Endocrinology)

Tuesday, 11 November 2014

Pioneering study combining the diabetes vaccine Diamyd® with GABA in children with type 1 diabetes approved by the US FDA

Diamyd Medical and University of Alabama at Birmingham has entered a Clinical Trial Agreement regarding the study, which will be conducted at Children’s of Alabama in Birmingham, USA. The combination has shown promising results in preclinical studies

Is the number of fast-food outlets in the neighbourhood related to screen-detected type 2 diabetes mellitus and associated risk factors?

These results suggest that increased exposure to fast-food outlets is associated with increased risk of type 2 diabetes and obesity, which has implications for diabetes prevention at a public health level and for those granting planning permission to new fast-food outlets (Public Health Nutrition)

The Effect of Medical Nutrition Therapy by a Registered Dietitian Nutritionist in Patients with Prediabetes Participating in a Randomized Controlled Clinical Research Trial

The results demonstrate that individualized medical nutrition therapy is effective in decreasing HbA1c level in patients diagnosed with prediabetes (Journal of the Academy of Nutrition and Dietetics)

Macular dysfunction is common in both type 1 and type 2 diabetic patients without macular edema

We demonstrated a significantly reduced sensitivity in both nonproliferative diabetic retinopathy groups without diabetic macular edema compared with healthy controls; this reduction was greater in Type 2 diabetic patients (Retina)

Monday, 10 November 2014

Healthcare Utilization and Costs in Diabetes Relative to the Clinical Spectrum of Painful Diabetic Peripheral Neuropathy

Patients with DPN, pDPN, and severe pDPN had significantly greater healthcare resource utilization and costs than patients with diabetes only, with the highest burden associated with severe pDPN (Diabetes and Its Complications)

Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up

Our data support insulin resistance as a predictor of diabetes in later life but, perhaps surprisingly, suggest this pathway is of negligible importance to CVD outcomes in the elderly (Diabetologia)

Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study

Bariatric surgery is associated with reduced incidence of clinical diabetes in obese participants without diabetes at baseline for up to 7 years after the procedure

Friday, 7 November 2014

BMI is an important driver of beta cell loss in type 1 diabetes upon diagnosis in 10-18 year old children

These observations indicate that increased body weight and increased insulin demand are associated with more rapid disease progression after diagnosis of type 1 diabetes in age group 10-18 years. This should be considered in studies of beta-cell function in type 1 diabetes (EJE)

Chronic inflammatory demyelinating polyneuropathy (CIDP) Variants in Diabetes: Measuring Treatment Response with A Small Nerve Fiber Test

Sudoscan electrochemical skin conductances have been found to correlate well with peripheral small fiber function and neuropathic symptoms in DPN (Diabetes and Its Complications)

Wednesday, 5 November 2014

Comparison of placental findings in type 1 and type 2 diabetic pregnancies

Both types of pregestational diabetes have significant impact on placental growth and development. The comparison between the two groups suggests different pathogenetic mechanisms and may be helpful for better management of diabetic pregnancy (Placenta)

Tuesday, 4 November 2014

CD247, a Novel T Cell–Derived Diagnostic and Prognostic Biomarker for Detecting Disease Progression and Severity in Patients With Type 2 Diabetes Mellitus

Our results suggest the use of CD247 as a biomarker in diabetic patients for evaluating the state of chronic inflammation that contributes to morbidity and mortality in this disease and for the prediction of future cardiovascular events (Diabetes Care)

Obesity lost weight with liraglutide

New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2% (Novo Nordisk)

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

In this first report of adding a well-tolerated combination of saxagliptin plus dapagliflozin to background metformin therapy in patients poorly controlled with metformin, greater improvements in glycemic control were obtained with triple therapy by the dual addition of saxagliptin and dapagliflozin than dual therapy with the addition of saxagliptin or dapagliflozin alone (Diabetes Care)

Monday, 3 November 2014

Efficacy and Safety of Linagliptin in Subjects With Long-Standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-Blind, Placebo-Controlled, Phase III Trials

This pooled analysis found that linagliptin was well tolerated and significantly improved hyperglycemia in a clinically challenging population of patients with long-standing T2DM ... hypothesis that regulation of glucagon release from pancreatic a cells may be of particular relevance for improving hyperglycemia in patients with long-term T2DM (Clinical Therapeutics)